ARTICLE | Clinical News
Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD
October 5, 2018 7:08 PM UTC
Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco.
Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported new data for GS-9674, its non-steroidal agonist of farnesoid X receptor (FXR; NR1H4)...